Ferroptosis/apoptosis inducer-5

Ferroptosis/apoptosis inducer-5 是一种具有口服活性的铁死亡 (Ferroptosis) 和凋亡 (Apoptosis) 诱导剂,可下调 GPX4 并上调 ACSL4,促进 ROS 生成、Caspase 级联激活、线粒体功能障碍 (Mitochondrial dysfunction) 以及改变 Bcl-2/Bax 平衡,在胰腺癌异种移植小鼠模型中可显著抑制肿瘤生长,可用于胰腺癌的研究。
产品编号: MS-B39658 CAS No.: 2243423-32-5 分子式: C53H72BrO3P 分子量: 868.01
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Ferroptosis/apoptosis inducer-5 是一种具有口服活性的铁死亡 (Ferroptosis) 和凋亡 (Apoptosis) 诱导剂,可下调 GPX4 并上调 ACSL4,促进 ROS 生成、Caspase 级联激活、线粒体功能障碍 (Mitochondrial dysfunction) 以及改变 Bcl-2/Bax 平衡,在胰腺癌异种移植小鼠模型中可显著抑制肿瘤生长,可用于胰腺癌的研究。

生物实验数据

生物活性 Ferroptosis/apoptosis inducer-5 is an orally active ferroptosis and apoptosis inducer that downregulates GPX4 and upregulates ACSL4, promotes ROS generation, Caspase cascade activation, mitochondrial dysfunction, and alters the Bcl-2/Bax balance, significantly inhibits tumor growth in a pancreatic cancer xenograft mouse model, and can be used for pancreatic cancer research.
IC50 & Target

Bax

 

Bcl-2

 

GPX4

 

ACSL4

 

体外研究
(In Vitro)

Ferroptosis/apoptosis inducer-5 (Compound 14) (48 h) 可强效且选择性地抑制 PANC-1 胰腺癌细胞的活力,其 IC50 为 1.36 μM,而对正常 3T3-L1 细胞的细胞毒性较弱。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h treatment) 可剂量依赖性地抑制 PANC-1 胰腺癌细胞的长期集落形成能力,在 2.0 μM 时可实现近乎完全的抑制。
Ferroptosis/apoptosis inducer-5 (0.125-2.0 μM; 24-48 h) 可呈浓度和时间依赖性抑制 PANC-1 胰腺癌细胞的增殖,在 48 h、0.25-2.0 μM 条件下可观察到显著效果。
Ferroptosis/apoptosis inducer-5 (0.125-0.5 μM; 24 h) 可剂量依赖性地抑制 PANC-1 胰腺癌细胞的迁移和侵袭潜能,在 0.5 μM、作用 24 h 时效果显著。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h) 可剂量依赖性地诱导 PANC-1 胰腺癌细胞发生 G0/G1 期阻滞,通过阻断复制周期的完成来抑制细胞增殖。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) 可剂量依赖性地升高 PANC-1 胰腺癌细胞内的 ROS 水平,其中 0.5 μM 作用 24 h 时即可出现显著升高。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h) 可呈剂量依赖性诱导 PANC-1 胰腺癌细胞发生凋亡,孵育 48 h 后的典型凋亡形态学变化可证明这一点。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) 可通过改变 Bcl-2/Bax 平衡、促进细胞色素 c 释放并激活半胱天冬酶级联反应,在孵育 24 h 后激活 PANC-1 胰腺癌细胞中的内源性线粒体凋亡通路。
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) 可通过下调 GPX4 并上调 ACSL4,在孵育 24 h 后诱导 PANC-1 胰腺癌细胞发生铁死亡。

Cell Cytotoxicity Assay

Cell Line: human pancreatic cancer PANC-1 cells, human choroidal melanoma C918 cells, mouse embryonic fibroblast 3T3-L1 cells
Concentration: 1.36 μM (PANC-1 IC50); 9.25 μM (3T3-L1 IC50)
Incubation Time: 48 h
Result: Showed potent cytotoxicity against PANC-1 cells with an IC50 of 1.36 μM, far superior to parent betulinic acid (IC50 = 79.29 μM).
Exhibited selective cytotoxicity with an IC50 of 9.25 μM against normal 3T3-L1 cells.
Displayed strong activity against C918 cells.

Cell Proliferation Assay

Cell Line: human pancreatic cancer PANC-1 cells
Concentration: 0.5-2.0 μM
Incubation Time: 48 h treatment, followed by 10 days of culture without compound
Result: Significantly inhibited PANC-1 colony formation in a concentration-dependent manner.
Almost completely suppressed colony formation at 2.0 μM.

Cell Proliferation Assay

Cell Line: human pancreatic cancer PANC-1 cells
Concentration: 0.125-2.0 μM
Incubation Time: 24 h, 48 h
Result: Inhibited PANC-1 cell proliferation in a concentration- and time-dependent manner.
Showed no significant effect at 0.125-0.5 μM over 24 h.
Produced significant inhibition at 0.25-2.0 μM over 48 h.

Cell Cycle Analysis

Cell Line: human pancreatic cancer PANC-1 cells
Concentration: 0.5-2.0 μM
Incubation Time: 48 h
Result: Induced dose-dependent G1 phase arrest in PANC-1 cells.
Increased G1 phase cell percentage.
Decreased S phase cell percentage.
Caused a slight reduction in G2 phase cell percentage.

Apoptosis Analysis

Cell Line: human pancreatic cancer PANC-1 cells
Concentration: 0.5-2.0 μM
Incubation Time: 48 h
Result: Induced a dose-dependent increase in apoptotic PANC-1 cells.
Caused enhanced blue fluorescence (nuclear condensation/fragmentation) and increased red fluorescence (cell membrane integrity loss).

Western Blot Analysis

Cell Line: human pancreatic cancer PANC-1 cells
Concentration: 0.5-2.0 μM
Incubation Time: 24 h
Result: Dose-dependently upregulated pro-apoptotic Bax and cytosolic cytochrome c.
Downregulated anti-apoptotic Bcl-2.
Increased levels of Cleaved-Caspase-9 and Cleaved-Caspase-3.\nDose-dependently downregulated anti-ferroptotic GPX4.
Upregulated pro-ferroptotic ACSL4.
体内研究
(In Vivo)

Ferroptosis/apoptosis inducer-5 (5-20 mg/kg;腹腔注射;每 2 天 1 次;共 28 天) 在胰腺癌异种移植模型中表现出剂量依赖性的显著抗肿瘤活性,在 20 mg/kg 剂量下实现了 68.9% 的肿瘤重量降低,同时保持良好的体内安全性。

Animal Model: C57BL/6 (female, 6 weeks old, 17-20 g, SPF grade, subcutaneous xenograft model via Panc02 cell injection)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p.; every 2 days; 28 days
Result: Reduced tumor weight by 37.1% relative to control.
Reduced tumor weight by 57.0% relative to control.
Reduced tumor weight by 68.9% relative to control, with no significant difference in tumor inhibition rate compared to positive control gemcitabine.
Showed dose-dependent reduction in tumor volume over the 28-day treatment period.
Induced dose-dependent tumor cell apoptosis (increased TUNEL-positive cells), reduced cell proliferation (decreased Ki-67 staining), and downregulated GPX4 expression (indicating ferroptosis induction) in tumor tissues.
Caused no significant pathological abnormalities in heart, liver, spleen, lung, or kidney tissues; serum levels of ALT, AST, BUN, and creatinine were statistically unchanged relative to control.

化学信息

分子量 868.01
分子式 C53H72BrO3P
CAS No. 2243423-32-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

Ferroptosis/apoptosis inducer-5 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础